MRTX Mirati Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRTX

Price (delayed)

$203.83

Market cap

$10.25B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.73

Enterprise value

$10.12B

Sector: Healthcare
Industry: Biotechnology
Website: https://www.mirati.com/

Highlights

Mirati Therapeutics's gross profit has soared by 95% YoY
MRTX's revenue has surged by 95% year-on-year
MRTX's equity is up by 27% YoY but it is down by 9% from the previous quarter
Mirati Therapeutics's net income has shrunk by 95% YoY and by 11% QoQ
The EPS has shrunk by 65% YoY and by 8% QoQ

Key stats

What are the main financial stats of MRTX
Market
Shares outstanding
50.28M
Market cap
$10.25B
Enterprise value
$10.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
16.48
Price to sales (P/S)
744.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
828.14
Earnings
Revenue
$12.22M
EBIT
-$329.23M
EBITDA
-$328.7M
Free cash flow
-$241.21M
Per share
EPS
-$7.73
Free cash flow per share
-$5.41
Book value per share
$12.37
Revenue per share
$0.27
TBVPS
$13.89
Balance sheet
Total assets
$619.85M
Total liabilities
$68.91M
Debt
$0
Equity
$550.94M
Working capital
$528.02M
Liquidity
Debt to equity
0
Current ratio
8.84
Quick ratio
8.6
Net debt/EBITDA
0.4
Margins
EBITDA margin
-2,690.5%
Gross margin
100%
Net margin
-2,694.8%
Operating margin
-2,764%
Efficiency
Return on assets
-54.2%
Return on equity
-60%
Return on invested capital
-78.1%
Return on capital employed
-59.6%
Return on sales
-2,694.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRTX stock price

How has the Mirati Therapeutics stock price performed over time
Intraday
0%
1 week
-4.22%
1 month
-13.2%
1 year
126.83%
YTD
-7.2%
QTD
-7.2%

Financial performance

How have Mirati Therapeutics's revenue and profit performed over time
Revenue
$12.22M
Gross profit
$12.22M
Operating income
-$337.68M
Net income
-$329.23M
Gross margin
100%
Net margin
-2,694.8%
Mirati Therapeutics's gross profit has soared by 95% YoY
MRTX's revenue has surged by 95% year-on-year
Mirati Therapeutics's net income has shrunk by 95% YoY and by 11% QoQ
The company's operating income has shrunk by 91% YoY and by 10% QoQ

Growth

What is Mirati Therapeutics's growth rate over time

Valuation

What is Mirati Therapeutics stock price valuation
P/E
N/A
P/B
16.48
P/S
744.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
828.14
The EPS has shrunk by 65% YoY and by 8% QoQ
MRTX's price to book (P/B) is 189% higher than its 5-year quarterly average of 5.7 and 65% higher than its last 4 quarters average of 10.0
MRTX's equity is up by 27% YoY but it is down by 9% from the previous quarter
MRTX's revenue has surged by 95% year-on-year
The price to sales (P/S) is 52% lower than the last 4 quarters average of 1565.4

Efficiency

How efficient is Mirati Therapeutics business performance
The ROS has soared by 84% QoQ
The company's return on equity fell by 23% YoY and by 5% QoQ
Mirati Therapeutics's return on assets has decreased by 21% YoY and by 4.2% QoQ
MRTX's return on invested capital is down by 9% year-on-year and by 6% since the previous quarter

Dividends

What is MRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRTX.

Financial health

How did Mirati Therapeutics financials performed over time
The total liabilities has soared by 90% YoY and by 17% QoQ
The quick ratio is down by 33% year-on-year and by 23% since the previous quarter
Mirati Therapeutics's debt is 100% less than its equity
MRTX's equity is up by 27% YoY but it is down by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.